SS-31 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
SS-31 results typically emerge over a 12-48 weeks in clinical trials research cycle. Early changes may be noticeable within the first 1-2 weeks, with more significant effects on improved muscle strength appearing by weeks 4-8. Results depend on dosage (4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV), consistency, and individual factors.
What Results Can You Expect From SS-31?
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction. Results depend on dosage (4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV), administration frequency (daily subcutaneous or weekly IV infusion), and individual factors.
The following timeline is based on standard 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV protocols over a 12-48 weeks in clinical trials cycle.
What Happens in Weeks 1-2 of SS-31?
During the first two weeks, SS-31 is establishing baseline blood levels. With a half-life of approximately 20-30 minutes, steady-state concentrations are typically reached within 4-5 half-lives.
Subtle changes researchers may notice: improved improved muscle strength, better sleep quality (commonly reported across peptide protocols), and mild injection site reactions that typically resolve.
What Changes by Weeks 3-4?
By week 3-4, the biological pathways SS-31 targets are becoming measurably activated. Selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and enhancing electron transfer efficiency. Reduces cytochrome C peroxidase activity, decreases reactiv.
More noticeable effects on improved muscle strength, enhanced cardiac function, increased ATP production begin to emerge. This is the phase where most researchers report the first clear evidence that the compound is working.
What Results Appear at Weeks 5-8?
Weeks 5-8 represent the peak response window for most Mitochondrial-targeting tetrapeptide compounds. Cumulative effects of consistent daily subcutaneous or weekly IV infusion dosing at 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV produce the most visible changes.
Key results during this phase typically include pronounced improvements in improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction. This is when before-and-after differences become most apparent.
What About Weeks 8-12 and Beyond?
For extended SS-31 cycles (12-48 weeks in clinical trials), weeks 8-12 often show the most dramatic cumulative results. However, diminishing returns and receptor adaptation can occur.
Many protocols include a washout period after the cycle to restore baseline sensitivity. Pairs with MOTS-C for comprehensive mitochondrial optimization — SS-31 stabilizes existing mitochondria while MOTS-C activates new mitochondrial biogenesis pathways.
How Can You Maximize SS-31 Results?
Consistent dosing at 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV daily subcutaneous or weekly IV infusion is the single biggest factor. Skipping doses or inconsistent timing significantly reduces outcomes.
Proper storage (reconstituted at 2-8°C), sourcing from COA-tested vendors, and supporting protocols (nutrition, sleep, training where applicable) all contribute to results.
Pairs with MOTS-C for comprehensive mitochondrial optimization — SS-31 stabilizes existing mitochondria while MOTS-C activates new mitochondrial biogenesis pathways.
Calculate Your SS-31 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for SS-31.
Open Calculator →What Is the Realistic SS-31 Timeline?
Expect initial effects in weeks 1-2, noticeable changes by weeks 3-4, and peak results during weeks 5-8 of a 12-48 weeks in clinical trials cycle. SS-31 is not instant — consistent dosing and patience are required.
SS-31 is fda-approved september 2025 (forzinity) for barth syndrome. phase 3 trials ongoing for other indications.
Complete Guide
SS-31 (Elamipretide) : Mitochondrial Peptide for Energy & Aging
Related Reading
- SS-31 Dosage Guide
- SS-31 Benefits
- SS-31 Side Effects
- SS-31 Stacking Guide
- SS-31 Cycle Guide
- SS-31 Research
Research-Grade Sourcing
If you're going to research SS-31, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is SS-31?
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics. It is researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
What is the recommended SS-31 dosage?
Common dosages: 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion. Cycle length: 12-48 weeks in clinical trials. Half-life: approximately 20-30 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of SS-31?
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.
Is SS-31 safe?
SS-31 has shown a favorable safety profile in research. FDA-approved September 2025 (FORZINITY) for Barth syndrome. Phase 3 trials ongoing for other indications. All research should follow appropriate safety protocols.